The fear of being exposed to more public shame while Congress and states are scrutinizing the biopharma industry may be having an impact on at least one of the games brand companies have been playing. In its first update, the FDA added just three drugs to its list of innovators that allegedly have made it difficult for would-be competitors to get the 1,500 to 5,000 units of a reference drug generally needed to develop a generic, bringing the total list to 54 drugs